International Stem Cell Corp. (ISCO)

[236T568]

$0.675 - New 52 week low!

[236T568]

Yikes! $0.71 low so far today

how long before the price drops to below $0.50?

a week?

a month?

this Fall?

[236T568]

what huge bounce?

today's vwap = .77 compared to yesterday's .74

So what caused the huge bounce today?

[Ecomike]

So what caused the huge bounce today?

[Doctor_Hari_Seldon]

The FDA does some good things, but they also force a lot of bullshit and costs that get in the way of human trials. ISCO went to Australia to avoid all that and get their therapeutic into 12 humans as soon as practical. All 12 had well tolerated procedures which is great. The FDA also considers safety and efficacy data from credible institutions around the world, such as the Florey Institute of Neuroscience in Australia, when evaluating further studies along the same or related lines.

[Doctor_Hari_Seldon]

Actually Correct.

[236T568]

actually, wrong - yet again

there are other matters to this company that allows one to call it a scam beyond its research and products

Look deep into ISCO SEC filings and into the backgrounds of the controlling Russian family and you will find your answers

Woww! That is a huge statement and I have not read much reasoning behind it.

I do not think there is any problem with the stem cells ISCO is working with because they are of different kind than those the newspaper you mentioned was talking about.

The big problem with ISCO (and it has always been so) is that the revenues obtained from other ISCO activities can not cover the cost of the trials. Thus the dilution issue

[tradero]

Woww! That is a huge statement and I have not read much reasoning behind it.

I do not think there is any problem with the stem cells ISCO is working with because they are of different kind than those the newspaper you mentioned was talking about.

The big problem with ISCO (and it has always been so) is that the revenues obtained from other ISCO activities can not cover the cost of the trials. Thus the dilution issue

[236T568]

actually, wrong

ISCO is a scam company

You are actually wrong.
KarinCA is actually quite correct.
Actual scams do not actually intracranially transplant stem cells into the human brain successfully in a world renowned neurological medical facility.
ISCO may sink or swim. But it is not a scam.

[Doctor_Hari_Seldon]

You are actually wrong.
KarinCA is actually quite correct.
Actual scams do not actually intracranially transplant stem cells into the human brain successfully in a world renowned neurological medical facility.
ISCO may sink or swim. But it is not a scam.

[Billy055]

I was hoping I could get some /positive/ advice by looking into your posts...hmm...

Can't you please explain the reasons you know so much about ISCO?

Or is this statement about any capital-seeking company, in general?

I believe these guys seem to be pretty reasonable:

http://www.edisongroup.com/publication/third-cohort-ready-to-go/7175/

Their coverage of some of the other companies seemed pretty good to me.

They Say their Valuation is $5.46 a share which isn't really that much considering the low number of shares out.

[236T568]

actually, wrong

ISCO is a scam company by any definition

Why ISCO is running trials in Australia.

ISCO isn't a scam company. They have two subsidiaries bringing in revenue. But, research and trials are very expensive. Cost is why many companies are running clinical trials in Australia. Go to the links I've provided rather than just reading the titles.

I'm sure you've heard of astrazeneca. Here's their take on doing trials in Australia.
https://www.astrazeneca.com.au/sustainability/About-us-research-development.html
Quote:
In partnership with doctors in Australia we focus our skills and resources on getting life-changing medicines to patients as quickly, safely and efficiently as possible. We are currently conducting research to develop new medicines in the following disease areas:

To find out more about clinical trials in Australia, please visit the dedicated Australian Government website www.australianclinicaltrials.gov.au

**********

HTTPS://WWW.OUTSOURCING-PHARMA.COM/ARTICLE/2019/04/29/AUSTRALIA-S-CLINICAL-TRIALS-INDUSTRY-IS-EXPERIENCING-UNPRECEDENTED-SUPPORT
Quote:
Australia’s clinical trials industry is experiencing ‘unprecedented support’
29-Apr-2019 By Melissa Fassbender

The Australian Government commits $100m to support rural, regional, and remote clinical trials – recognizing the importance of a “vibrant clinical trial ecosystem in underpinning a world-class health care system,” says industry expert.


**********

Australia: Preferred Destination for Early Phase Clinical Trials
https://ww3.frost.com/files/6514/7374/3781/Novotech_WP_20160701_v2.1.pdf

**********

As I said earlier, dilution has been the main problem here. Not unheard of in biotech. Biotech is very risky for early investors and I got involved way too early with this one. But, that is my fault, not the company's fault. It's been off my radar for awhile now, but, I'm watching again.

[MinnieM]

Why ISCO is running trials in Australia.

ISCO isn't a scam company. They have two subsidiaries bringing in revenue. But, research and trials are very expensive. Cost is why many companies are running clinical trials in Australia. Go to the links I've provided rather than just reading the titles.

I'm sure you've heard of astrazeneca. Here's their take on doing trials in Australia.
https://www.astrazeneca.com.au/sustainability/About-us-research-development.html

In partnership with doctors in Australia we focus our skills and resources on getting life-changing medicines to patients as quickly, safely and efficiently as possible. We are currently conducting research to develop new medicines in the following disease areas:

To find out more about clinical trials in Australia, please visit the dedicated Australian Government website www.australianclinicaltrials.gov.au

**********

HTTPS://WWW.OUTSOURCING-PHARMA.COM/ARTICLE/2019/04/29/AUSTRALIA-S-CLINICAL-TRIALS-INDUSTRY-IS-EXPERIENCING-UNPRECEDENTED-SUPPORT

Australia’s clinical trials industry is experiencing ‘unprecedented support’
29-Apr-2019 By Melissa Fassbender

The Australian Government commits $100m to support rural, regional, and remote clinical trials – recognizing the importance of a “vibrant clinical trial ecosystem in underpinning a world-class health care system,” says industry expert.

**********

Australia: Preferred Destination for Early Phase Clinical Trials
https://ww3.frost.com/files/6514/7374/3781/Novotech_WP_20160701_v2.1.pdf

**********

As I said earlier, dilution has been the main problem here. Not unheard of in biotech. Biotech is very risky for early investors and I got involved way too early with this one. But, that is my fault, not the company's fault. It's been off my radar for awhile now, but, I'm watching again for the upcoming trial results.

[236T568]

So is that why scam company ISCO has been avoiding clinical trials in the U.S. and now conducting them in other countries like Australia?

https://www.otcmarkets.com/stock/ISCO/news/International-Stem-Cell-Corporation-Completes-Enrollment-and-Dosing-in-its-Parkinsons-Disease-Clinical-Trial?id=226152

Correct... It's an article, not a press release. I first saw this on the FDA site. But, it's still unrelated to ISCO since different types of stem cells are used along with different methods.

Just like not all tech is the same. Not all stem cells are the same.

ISCO has a type of stem cell technology that should eliminate most issues facing stem cell companies. It's a tough nut to crack since most stem cell therapies cause enough harm that they are too risky.... that's why so many are out of business. Go to ISCO site and read about how they derive their stem cells.

It will be interesting to see final results of the Parkinson trial.

Dilution has been the main problem here.

[MinnieM]

Correct... It's an article, not a press release. I first saw this on the FDA site. But, it's still unrelated to ISCO since different types of stem cells are used along with different methods.

Just like not all tech is the same. Not all stem cells are the same.

ISCO has a type of stem cell technology that should eliminate most issues facing stem cell companies. It's a tough nut to crack since most stem cell therapies cause enough harm that they are too risky.... that's why so many are out of business. Go to ISCO site and read about how they derive their stem cells.

It will be interesting to see final results of the Parkinson trial.

Dilution has been the main problem here.

[236T568]

actually, no

1. It is not a press release

2. It is an article from a newspaper, the Washington Post.

3. In involves the field of Stem Cells, which is exactly the field that ISCO is involved in.

The posted PR is unrelated to ISCO.
The stem cells used are unrelated to the type ISCO uses.
The procedure is unrelated to the procedure used in ISCO clinical trial.

All the way around, the company in the posted pr and ISCO are unrelated. But, most importantly, unrelated in type of stem cells used.

[MinnieM]

The posted PR is unrelated to ISCO.
The stem cells used are unrelated to the type ISCO uses.
The procedure is unrelated to the procedure used in ISCO clinical trial.

All the way around, the company in the posted pr and ISCO are unrelated. But, most importantly, unrelated in type of stem cells used.

[236T568]

$0.70 - New 52 week low!

[236T568]

FDA wins groundbreaking case against for-profit stem cell company


https://www.washingtonpost.com/health/fda-wins-groundbreaking-case-against-for-profit-stem-cell-company/2019/06/03/498373fa-864e-11e9-98c1-e945ae5db8fb_story.html?utm_term=.a160cf271532

By William Wan and
Laurie McGinley June 3 at 7:00 PM

In a decision expected to send a chill through the booming stem cell industry, a federal judge ruled in favor of the Food and Drug Administration on Monday in a lawsuit against a Florida-based stem cell company whose treatments have blinded at least four patients.

Judge Ursula Ungaro agreed that the FDA has the authority to regulate a procedure that has become widespread in the burgeoning industry — using patients’ fat to create a stem cell treatment.

The judge ruled that the FDA is entitled to an injunction ordering U.S. Stem Cell to halt the procedure.

The judgment represents a major victory for the government, which has increasingly tried to constrain the industry even as it has rapidly expanded in recent years.

“This case is an important victory in the FDA’s work to protect the public health,” the agency said in a statement. “We’ve been taking action, like this case, against clinics that abuse the trust of patients and endanger their health. We will continue to promote the sound and scientific development of regenerative medicine products, but we will not tolerate those in this field who try to skirt the law and put patients in harm’s way.”


Scientists, medical associations and health officials have criticized stem cell clinics for selling treatments unproven by science and unapproved by the government for a wide spectrum of unrelated ailments, such as Parkinson’s disease, multiple sclerosis, joint pain and erectile dysfunction.

“This decision says the FDA has the authority to define a certain kind of stem cell product as a drug product” that requires FDA approval and compliance with other agency rules, said Paul Knoepfler, a stem cell biologist at the University of California at Davis. “There are potentially hundreds of clinics using the same model, and this ruling basically says the FDA can — assuming this is not overturned on appeal — say you are using an unapproved drug, and that’s a big deal.”

Beginning in 2015, at least four patients were blinded after U.S. Stem Cell and clinics associated with the company injected stem cell treatments into their eyes.


The FDA’s slow initial response to patient injuries permitted U.S. Stem Cell to continue operating four years after those first reports of blindness. Although the company stopped injecting its fat-derived treatments into eyes after the patients sued, it continues to sell the therapy to people with spinal injuries, Parkinson’s disease, multiple sclerosis and other serious chronic conditions.

Last year, just three weeks after the government filed suit, an additional patient had a catastrophic reaction after visiting a clinic in South Miami, Fla., that is affiliated with U.S. Stem Cell. A 59-year-old woman felt faint and started vomiting two hours after receiving injections for arthritis pain.

Her case was described in an “adverse event” report filed with the FDA and obtained by The Washington Post through the Freedom of Information Act.


In her judgment Monday, Ungaro said that unless the company is ordered to stop, “there is a reasonable likelihood that Defendants will continue to violate” regulations by offering the unapproved treatments.

Making $6.7 million in revenue last year, U.S. Stem Cell operates three clinics and has trained doctors at 150 others, making it one of the most influential stem cell companies in the nation. Over the past year, it has hired a top law firm to defend against the lawsuit and cultivated formidable allies with close ties to President Trump, including GOP operative Roger Stone and Newsmax chief executive Christopher Ruddy.

U.S. Stem Cell and its chief science officer Kristin Comella did not return calls for comment.

In the lawsuit, the government accused the company of “openly violating the law and endangering patients by manufacturing an unapproved, experimental drug.” Responding in court, the company called the FDA’s new rules “a power grab” and argued its treatment is a medical procedure that can’t be regulated as a drug.


Ungaro noted in her summary judgment that the clinic makes “numerous claims” about the benefits provided by the treatment derived from fat cells for an array of illnesses, including Parkinson’s disease, lung disease and diabetes. She added that the clinic has boasted its therapy is superior to conventional medicine in treating these serious diseases. She also said the FDA inspected the clinic seven times between October 2015 and May 2017.

The ruling does not automatically prevent other companies from offering the same treatment, said Sam Halabi, a law professor at the University of Missouri. “But it sends a very strong signal to the market, and other judges will look at this decision quite seriously and use it as a crucial road map for similar lawsuits that appear before them,” he said.

Leigh Turner, a bioethicist at the University of Minnesota and a longtime critic of the stem cell clinics, welcomed the decision but questioned whether it would prompt other companies to get out of the business. “Are some of them just going to say there are so many businesses out there that the FDA won’t knock on our door so we will just keep going?” he asked.


Turner said some clinics will “play the odds” and continue performing the fat-based procedures, while others may simply shift into questionable types of stem cell treatment not addressed in the ruling — such as birth-related stem cell products. “I don’t expect to see the disappearance of the direct-to-consumer industry,” he said. “These businesses are too dug in, and there’s too much money to be made.”

Former FDA commissioner Scott Gottlieb called the decision a “pivotal ruling” indicating that the FDA “is on strong footing” in challenging the practices of the clinics offering unapproved stem cell therapies. “This was a must-win case for the FDA,” he said. “It’s highly significant in that it establishes the agency’s ability to regulate in this space, and it paves the way for the agency to bring more enforcement actions.”

Gottlieb, who stepped up FDA action against the clinics offering unproven treatments, said the decision sends a strong message to the industry and will bolster agency efforts to take immediate action “against firms putting patients at immediate risk.”

Read more

[236T568]

$0.75 - New 52 week low!

[236T568]

Oh my! $0.82 - 52 week low!

[rocco_p_coletrain]

Buy the dip.

[236T568]

actually, over 11,000 shares have traded today for ISCO

mostly in the $0.80's

Look for below $0.50 in the near future

A whopping 850 share trade at .85. Wow. When stem cell stocks are back in play this will erupt. Buy now.

[rocco_p_coletrain]

A whopping 850 share trade at .85. Wow. When stem cell stocks are back in play this will erupt. Buy now.

[dyp]

or here?
why not @ 82 cents.
I suspect even less
with that dismal financial report.

[236T568]

Whoaaa! $0.82 - New 52 wk low!

[Doctor_Hari_Seldon]

That is precisely it. He fully understands that. Was discussed in detail by ISCO. I don't quite understand why he insists on placing a potato chip company standard on ISCO. It just does not apply.

[akamaii]

Russian power lol I had a huge position here 4 years ago 100k range

[rocco_p_coletrain]

The whole stock market is one big scam.

[236T568]

and yet another ISCO scammy PAID PROMOTIONAL RESEARCH REPORT issued

NEWS -- International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research

CARLSBAD, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $43 million, up from $42 million in December 2018, by Edison Investment Research ("Edison")*, a world-renowned investment intelligence firm with more than one hundred analysts, investment experts, and roadshow professionals, with offices in North America, Europe, the Middle East and Asia.

The research report is available on Edison's website and can be accessed here. The report features an analysis of ISCO's financial data, along with an investment summary that showcases the Company's cell therapy for Parkinson's disease and traumatic brain injury as key industry differentiators.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:

http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

*The Edison report was sponsored by the Company.

Safe harbor statement

Statements pertaining to anticipated developments, expected pre-clinical studies (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts

International Stem Cell Corporation
Russell Kern, PhD
Executive Vice President, Chief Scientific Officer
mailto://[e-mail]

Joe Green
Investor Relations
Edison Inc.
mailto://[e-mail]
[phone]

[rocco_p_coletrain]

Great time to buy right here.

[Paulness]

NEWS -- International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research

CARLSBAD, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $43 million, up from $42 million in December 2018, by Edison Investment Research ("Edison")*, a world-renowned investment intelligence firm with more than one hundred analysts, investment experts, and roadshow professionals, with offices in North America, Europe, the Middle East and Asia.

The research report is available on Edison's website and can be accessed here. The report features an analysis of ISCO's financial data, along with an investment summary that showcases the Company's cell therapy for Parkinson's disease and traumatic brain injury as key industry differentiators.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (http://www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:

http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

*The Edison report was sponsored by the Company.

Safe harbor statement

Statements pertaining to anticipated developments, expected pre-clinical studies (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts

International Stem Cell Corporation
Russell Kern, PhD
Executive Vice President, Chief Scientific Officer
mailto://[e-mail]

Joe Green
Investor Relations
Edison Inc.
mailto://[e-mail]
[phone]

[ACanJadaS]

Too expensive and over regulated is my assumption. Slowest trials in the world at a steep price.

[236T568]

Oh, look - the study done in Australia

I guess there weren't any US Medical entities willing to work with ISCO on this study

wonder why?

This clinical trial, which involved 12 patients with Parkinson’s disease, was conducted in collaboration with investigators from Royal Melbourne Hospital, a leading medical institution with an international reputation for excellence.

[Paulness]

NEWS -- International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial

CARLSBAD, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the completion of subject enrollment in its phase 1 clinical trial of ISC-hpNSC® for the treatment of Parkinson’s disease. The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 clinical study, was successfully transplanted with the highest dose of ISC-hpNSC® cells. This clinical trial, which involved 12 patients with Parkinson’s disease, was conducted in collaboration with investigators from Royal Melbourne Hospital, a leading medical institution with an international reputation for excellence.

"We are excited to announce the completion of enrollment of the world’s first approved human pluripotent stem cell-based clinical trial for the treatment of Parkinson's disease. This is a major milestone for the Company and we expect to announce complete clinical results of this phase 1 clinical trial in the first half of 2020," commented ISCO's Co-Chairman and CEO Andrey Semechkin, PhD.

“In addition, now that we have completed the most expensive stage of the phase 1 clinical trial, ISCO will have more resources available to invest in growing and developing its commercial business, where we have recently made significant progress,” he continued.

The goal of this study is to assess the safety and incidence of treatment-emergent adverse events after intracerebral transplantation of 30 million, 50 million, and 70 million ISC-hpNSC® cells into the substantia nigra and striatum of patients with Parkinson’s disease. Thus far there have been no serious adverse events related to the transplanted ISC-hpNSC®, which is a very significant achievement due to the invasive nature of the transplantation procedure. Preliminary efficacy is also evaluated through secondary endpoints, although no definitive conclusions can be drawn due to the fact that this is a clinical study with no placebo control group. Secondary endpoints assess the change from baseline in different neurological scales such as Unified Parkinson’s Disease Rating Scale, Parkinson’s Disease Quality of Life Questionnair-39, and Patient motor diary. After transplantation, patients are evaluated for 12 months (active phase of the study) with an additional 5-year observational follow-up period to assess the safety of ISC-hpNSC®. Eight patients have already completed the 12-month study and entered the follow-up phase.

Interim results of this study will be presented at the upcoming 2019 American Academy of Neurology 71st Annual Meeting in Philadelphia, PA on May 5th, 2019.

About Parkinson's disease

Parkinson's disease is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related. These symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease. Depression is the most common psychiatric symptom. Parkinson's disease is more common in people over the age of 50.

There are no approved treatments that restore the damaged dopaminergic neurons. Medications typically used in the treatment of Parkinson's disease, levodopa and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective, while at the same time frequently producing a complication marked by involuntary writhing movements. There are over 10 million people afflicted with Parkinson's disease, worldwide. In 2013 Parkinson's disease resulted in about 103,000 deaths, globally. In 1990, the death toll recorded was 44,000.

About ISC-hpNSC®

International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are free of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and neuroregeneration to the dying dopaminergic neurons of the recipient Parkinson's disease brain. Additionally, ISC-hpNSC® is safe, well tolerated and has shown not to cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide, through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, clinical studies expectations (including timing), resource availability, progress of research and development, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.

Contacts

International Stem Cell Corporation
Russell Kern, PhD
Executive Vice President, Chief Scientific Officer
mailto://[e-mail]

Joe Green
Investor Relations
Edison Inc.
mailto://[e-mail]
[phone]

[236T568]

ISCO $1.04 low so far today!

[Doctor_Hari_Seldon]

Seems like confusion over too many potato chips. ISCO is not in the potato business. They are in the medical therapeutics business via stem cell technology.

[Stock62]

Thanks Doctor for the uplifting year end report and exchange upgrade! Congrats to ISCO

[236T568]

so......of the three business areas that produce revenues, only ONE, the lower margined Reagent product line, is the only one that had increased revenues...

and say, why don't you tell us what ISCO has done in replacing the CFO that resigned almost a year ago, the 3rd CFO in the last 5 years?

oops, you can't because the Russian girl that is the General Counsel for ISCO is now also the Principal Financial Officer

So it appears that no one wants to work for ISCO that would involve being responsible for its financial statements filed with the SEC. What does that tell you about what is going on with this Russian controlled company?

Looks like a good year end report to me. I don't see any reason for negativity. Sad that it seems that is all some wish to see and hear these days. Kudos to ISCO for a good year end report and the exchange upgrade. If the subs continue to improve, they alone are worth today's capitalization and more. Oh well, go figure, still flying too low under the radars I guess.

[Doctor_Hari_Seldon]

Looks like a good year end report to me. I don't see any reason for negativity. Sad that it seems that is all some wish to see and hear these days. Kudos to ISCO for a good year end report and the exchange upgrade. If the subs continue to improve, they alone are worth today's capitalization and more. Oh well, go figure, still flying too low under the radars I guess.

[236T568]

The ISCO 10K is due Monday

Maybe the bad news from the 10K leaked out

Why?

[rteest]

Why?

[236T568]

ISCO hits $1.03 - New 52 week low!

[rteest]

What happened???

[Doctor_Hari_Seldon]

Good News going to OTCQX. That is the top tier on the OTC.

https://finance.yahoo.com/news/otcqx-vs-otcqb-vs-pink-171211773.html

[Paulness]

NEWS -- OTC Markets Group Welcomes International Stem Cell Corporation to OTCQX

NEW YORK, March 4, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced International Stem Cell Corporation (OTCQX: ISCO), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, has qualified to trade on the OTCQX® Best Market. International Stem Cell Corporation upgraded to OTCQX from the OTCQB® Venture Market.

International Stem Cell Corporation begins trading today on OTCQX under the symbol "ISCO." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on http://www.otcmarkets.com.

"Congratulations to International Stem Cell Corporation on upgrading to the OTCQX Best Market," said Jason Paltrowitz, Director of OTC Markets Group International Ltd. and EVP of Corporate Services at OTC Markets Group. "By trading on the OTCQX Market, entrepreneurial companies provide investors with a transparent, better informed public market to research and trade their shares. We look forward to supporting International Stem Cell Corporation as the company works to build long-term shareholder value for its investors."

"I'm glad that ISCO was able to move up to the OTCQX Best Market, which is a significant milestone for the company as it enables a broader range of US investors to participate in our growth," said Andrey Semechkin, PhD, ISCO's Co-Chairman and CEO. "We thank OTC Markets Group for their continued support in facilitating greater transparency and accessibility for our US stakeholders."

International Stem Cell Corp. was sponsored for OTCQX by Securities Law USA, PC, a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (http://www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com).

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit http://www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

View original content to download multimedia: http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-international-stem-cell-corporation-to-otcqx-300805340.html

[Paulness]

NEWS -- International Stem Cell Corporation Commences Trading on the OTCQX Best Market

CARLSBAD, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (ISCO) (http://www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been approved to trade on the OTCQX Best Market in the United States. International Stem Cell Corporation upgraded to the OTCQX from the OTCQB Venture Market.

“I’m glad that ISCO was able to move up to the OTCQX Best Market, which is a significant milestone for the company as it enables a broader range of US investors to participate in our growth,” said Andrey Semechkin, PhD, ISCO’s Co-Chairman and CEO. “We thank the OTC Markets Group for their continued support in facilitating greater transparency and accessibility for our US stakeholders.”

The company will begin trading today under the ticker “ISCO” on the OTCQX. United Stated investors can find current financial disclosure and Real-Time Level 2 quotes for the company at http://www.otcmarkets.com.

OTC Markets Group Inc., located in New York, N.Y., operates the world's largest electronic interdealer quotation system for broker dealers to trade over 10,000 securities not listed on any other United States stock exchange.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (http://www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:

http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell.

Safe harbor statement

Statements pertaining to anticipated developments and growth, progress of research and development, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation
Russell A. Kern, PhD
Phone: [phone]
mailto://[e-mail]

Or

Edison Advisors
Joseph Green
Senior Vice President, Investor Relations
[phone]
mailto://[e-mail]

[Paulness]

NEWS -- International Stem Cell Corporation Publishes Successful Results in Traumatic Brain Injury

CARLSBAD, Calif. -- February 13, 2019 -- InvestorsHub NewsWire -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the results of the Company’s preclinical studies in traumatic brain injury (TBI) have been published in Theranostics, a prestigious peer-reviewed medical journal. The publication, titled, “Human parthenogenetic neural stem cell grafts promote multiple regenerative processes in a traumatic brain injury model,” demonstrated that the clinical-grade neural stem cells used in our Parkinson’s disease clinical trial, ISC-hpNSC®, significantly improve TBI-associated motor, neurological, and cognitive deficits without any safety issues. The paper is available on the Company’s website.

The article details ISCO’s preclinical studies in TBI conducted by world-renowned Dr. Cesar Borlongan, Director and Distinguished Professor of the Center of Excellence for Aging and Brain Repair at the University of South Florida Morsani College of Medicine.

“ISCO’s human parthenogenetic neural stem cells may have a strong therapeutic value for patients suffering from traumatic brain injury (TBI). Transplantation of the neural stem cells in the brain were able to restore motor function, learning, and memorizationin the TBI rodent model. Animals receiving the cells had increased neuronal survival and reduced inflammation compared to the untreated group,” commented Prof. Borlongan.

Rodents injected with moderate and high doses of ISC-hpNSC® significantly improved motor function, neurologic function, and cognition compared to the control animals receiving no treatment. Also, histological analysis demonstrated increased expression of neural and myelination markers and decreased reactive gliosis and inflammation in the brains of animals receiving moderate and high doses of ISC-hpNSC® compared to the untreated group.

“The results of these studies add to the validation of ISC-hpNSC® as a potential therapeutic platform to treat a broad spectrum of neurological disorders. There is currently no approved treatment for TBI and it represents a significant unmet medical need with millions affected annually. For ISCO this may open new opportunities with large market potential,” commented Russell Kern, PhD, ISCO's EVP, Chief Scientific Officer.

According to the World Health Organization, the global incidence for TBI is approximately 10 million people annually.TBI is also a leading cause of death and disability in the United States, contributing to approximately 30% of all injury deaths.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (http://www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, clinical studies expectations (including plans for future clinical trials), progress of research and development, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation
Russell A. Kern, PhD
Phone: [phone]
Email: mailto://[e-mail]

Edison Advisors
Tirth Patel
Vice President, Investor Relations
[phone]
mailto://[e-mail]

[Doctor_Hari_Seldon]

Little pieces here and there keep coming together for this company. The new patent is good to have. Active cosmetics can grow to be a huge seller with good margins in a vanity driven society. Continued growth is indicative of positive acceptance.

[Paulness]

NEWS -- International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business

CARLSBAD, CA. -- January 15, 2019 -- Investorshub NewsWire -- International Stem Cell Corporation (OTCQB: ISCO) (http://www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based, clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company US Patent No. 10,172,890 on the topical use of lysate from human parthenogenetic (non-embryonic) stem cells to visibly improve signs of skin aging. The patented stem cell lysate is encapsulated and delivered from protective liposomes, and is combined with antioxidants, vitamins and peptides to provide skin benefits including reducing the depth/number of facial fine lines and wrinkles, increasing skin elasticity/firmness, and improving skin hydration. This proven to be effective technology used in the products was developed by key ISCO scientists, who brought neural stem cells to the clinical trial for the treatment of Parkinson’s disease.

“It is important that ISCO’s intellectual property portfolio continues to expand and we are excited to receive this US patent covering a technology used in Lifeline’s stem cell-based product line, which won various prestigious awards and has been receiving positive feedback both from consumers and well-known doctors since 2010 when we launched the product line” – commented Russell Kern, PhD, Co-Founder and CEO of Lifeline Skin Care, Inc.

ISCO’s wholly-owned subsidiary Lifeline Skin Care®, Inc. is a cosmeceutical business which develops, manufactures and markets anti-aging topical products using a proprietary extract derived from human parthenogenetic (non-embryonic) stem cells (hpSC) that has been shown to have a beneficial effect on skin cells. Currently Lifeline has developed and markets nineteen products. The products have been clinically tested by third party to ensure safety and efficacy.

Lifeline Skin Care’s products are sold nationally and internationally through a branded website http://www.lifelineskincare.com, various e-tailers such as Amazon, as well as through dermatology and cosmetic surgery offices, medical, day and resort spas. The goal of Lifeline is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (http://www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Contacts:
International Stem Cell Corporation
Russell A. Kern, PhD
Phone: [phone]
Email: mailto://[e-mail]

or

Edison Advisors
Tirth Patel
Vice President, Investor Relations
[phone]
mailto://[e-mail]